Comparative study on efficacy of a new combined vaginal preparation (Neo Penotran) versus Flagystatin in the treatment of common vaginitis
- Author:
Dang Le Dung Hanh
- Publication Type:Journal Article
- Keywords:
Vaginitis
- MeSH:
Vaginitis;
Therapeutics
- From:Ho Chi Minh city Medical Association
2005;10(1):6-8
- CountryViet Nam
- Language:Vietnamese
-
Abstract:
A randomized controlled trial was carried out on two groups of patients who were received either Flagystatine (nystatin 1000000 UI/metronidazol 500 mg) or Neo Penotran (miconazol 100mg/metronidazol 500 mg), twice a day for 7 days. Gynecological and microbiological assessments were carried out before treatment and 14 days after the first visit. In Flagystatine and Neo Penotran groups, clinical cure rates were 42% and 77.9% respectively; microbiological cure rates were 68.2% and 72.1%. In Neo Penotran group, functional symptoms were reduced more than organic symptom (84.8% and 79.1%, respectively). This difference was not so remarkable in Flagystatine group (64.8% and 65.95, respectively). Side effects of Neo Penotran were insignificant. Neo Penotran therapy without supportive treatment had higher efficacy in vaginitis at dosage of two pill a day in 7 days. The drug showed effects in both of function symptoms and organic symptoms, in clinical and paraclinical
